ECM Prosthetic Valves Resolving Calcification and Flow Trade-offs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prosthetic heart valves, particularly xenograft tissue valves, face issues such as in vivo calcification, cytotoxicity, and suboptimal blood flow modulation, which can lead to complications like calcification and disruption of blood flow, necessitating improved designs that minimize these drawbacks and enhance tissue regeneration and structural integrity.
Innovation Solution
The development of prosthetic tissue valves using decellularized extracellular matrix (ECM) derived from mammalian sources, such as small intestine submucosa, with integrated biologically active agents like growth factors and pharmacological agents like statins, which are designed to securely attach to cardiovascular structures via annular rings and structural rings, promoting modulated healing, tissue proliferation, and adaptive regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional prosthetic heart valves are used, then valve replacement function is achieved, but in vivo calcification and cytotoxicity occur
Solution Approach 1:
The patent changes the material parameters of the prosthetic valve by using decellularized extracellular matrix (ECM) instead of conventional materials. This material parameter change eliminates in vivo calcification and cytotoxicity while maintaining valve function, directly resolving the technical contradiction between reliability and harmful factors.
Solution Approach 2:
The patent employs composite material construction by combining decellularized ECM with biologically active agents and pharmacological agents. This composite approach creates a valve that is both biocompatible (reducing harmful factors) and functional (maintaining reliability), solving the contradiction through material composition optimization.
2Reliability
If conventional prosthetic valves are used, then valve replacement is achieved, but blood flow modulation is suboptimal
Solution Approach 1:
The patent optimizes blood flow parameters by designing the valve structure to modulate flow dynamics. The decellularized ECM material and structural configuration work together to improve blood flow modulation, reducing turbulence and disruption while maintaining effective valve function.
3Reliability
If decellularized ECM with biologically active agents is used, then tissue regeneration is enhanced, but device complexity increases
Solution Approach 1:
The patent merges multiple functions into a single integrated valve structure. The decellularized ECM serves as both the structural framework and the carrier for biologically active agents and pharmacological agents. This consolidation enhances tissue regeneration while managing device complexity by combining rather than separating functional components.
Data Source
AI summary
A prosthetic valve comprising a tubular shaped sheet member comprising an extracellular matrix (ECM) composition, the sheet member having a plurality of ribbons having proximal and distal ends, the distal ends of the ribbons projecting from the sheet member proximal end.